What Are Peptides? Medicines, Supplements and Research Compounds Explained

A peptide is a molecule made from linked amino acids, the building blocks also found in proteins. That describes its structure. It does not, on its own, tell you what a product does or whether it is appropriate for you. NCI definition.

The useful question is more specific: which molecule, in which product, used in which way, for which purpose? A conversation about “peptides” can otherwise mix medicines, cosmetics and experimental compounds that have very different evidence behind them.

Four things that often get called peptides

Category	What you may encounter	What to check
Prescription medicines	A named medicine with a defined formulation and label	The exact product, approved uses and prescribing information
Dietary supplements	Products marketed as collagen peptides or other supplements	The ingredient, intended use and evidence for the finished product
Cosmetics	Skin-care formulas containing peptide ingredients	Whether the evidence concerns that formula and topical use
Research compounds	Molecules promoted through laboratory research or early studies	Whether there is meaningful human evidence and an approved medicine

FDA treats drugs, supplements and cosmetics differently. A supplement or cosmetic being available for sale does not mean it received the same premarket approval as a drug. FDA explanation.

These categories are a way to organize questions, not a ranking of every product. A familiar ingredient name does not remove the need to examine the finished product.

Evidence belongs to a specific question

Consider semaglutide. The STEP 1 randomized trial studied a defined injectable treatment in adults with overweight or obesity, alongside lifestyle support. That is useful evidence about that intervention and population. It cannot establish the performance of every product advertised using the same ingredient name. STEP 1.

Now consider BPC-157, often discussed in recovery conversations. FDA’s 2026 assessment describes substantial evidence and product-characterization limitations and states that it is not a component of an FDA-approved drug. A compelling anecdote about recovery does not fill those gaps. FDA assessment.

When you see a claim, look for:

• Who was studied? People with the condition in question, healthy volunteers, animals or cells?
• What was measured? Symptoms, daily function and disease outcomes, or a laboratory marker?
• What was compared? A control group, a different treatment, or only a person’s recollection?
• What exactly was used? The formulation, route and duration need to match the claim.

These questions help you understand a study. They do not turn a single study into personal medical advice.

The route and formulation matter

A cream, tablet and injection are different ways of delivering a substance. Evidence about one should not silently become a claim about another. In the same way, findings in a related molecule are not automatically findings in the product being sold.

An easy reading habit is to write the full claim in one sentence: “This specific product was studied for this outcome, in these people.” If a source cannot support the sentence, make the uncertainty visible.

Our peptide field guide puts molecule identity, documented outcomes, evidence type and US status side by side. Open an entry to see the limitations and direct sources, rather than treating its category as a recommendation.

Where a clinician fits

For prescription weight-management medicines, NIDDK describes treatment selection as an individual decision that considers health history, other medicines, benefits, risks and cost. These medicines sit within a broader care plan. NIDDK guidance.

You do not need to arrive with a product already chosen. You can arrive with a goal, the claim that caught your attention, and a few clear questions. Our clinician conversation checklist gives you a place to start.

Sources and further reading

1. National Cancer Institute: peptide definition (opens in a new tab)
2. NIDDK: prescription medications for overweight and obesity (opens in a new tab)
3. FDA: Is It Really FDA Approved? (opens in a new tab)
4. FDA: BPC-157 evidence assessment, 2026 (opens in a new tab)
5. STEP 1: semaglutide trial in the New England Journal of Medicine (opens in a new tab)

Sources were checked on October 7, 2026. Prices, labels and policies can change. Linked studies being peer reviewed does not mean this article has been clinically reviewed.